Loading company
Surrozen, Inc.
SRZN · Nasdaq · ·
Next earnings: November 6, 2026
$31.87+7.5%Sep 29 close
- 1M
- +42.1%
- 6M
- +16.1%
- 1Y
- +147.3%
- 5Y
- -73.7%
SRZN · Nasdaq · ·
Next earnings: November 6, 2026
$31.87+7.5%Sep 29 close
Surrozen, Inc. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $5M | $983K | +408.65% |
| Profit | $50.2M | $39.7M | +26.24% |
| Profit per share | $2.17 | $2.55 | -14.99% |
| Free Cash Flow | -$7.4M | -$6.1M | -21.25% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We continue to execute our strategy of building a leading ophthalmology franchise centered on the therapeutic potential of Wnt biology,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Retinal Diseases Surrozen is developing SZN-8141 for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (wet AMD). SZN-8141 combines Frizzled 4 (Fzd4) agonism and vascular endothelial growth factor (VEGF) antagonism and has the potential to provide benefits over treatment with single mechanism agents against these targets. The current standard of care for diabetic retinopathy (including DME), retinal vein occlusion and wet AMD is intravitreal administration of anti-VEGF therapies, including monotherapies and dual-pathway agents targeting VEGF and Ang-2. In addition, MK-3000, a Fzd4 monotherapy, has demonstrated proof of concept in DME in a clinical trial. We believe SZN-8141 has the potential to treat multiple retinopathy indications and be differentiated from existing therapies. Data generated in preclinical models of retinopathy demonstrated that SZN-8141 stimulated Wnt signaling and induced normal retinal vessel regrowth while suppressing pathological vessel growth.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Surrozen, Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Surrozen, Inc. has no earnings call transcript available.